Have a feature idea you'd love to see implemented?
Let us know!
CLYM Climb Bio Inc.
Price (delayed)
$4.64
Market cap
$311.16M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.15
Enterprise value
$88.12M
Highlights
CLYM's quick ratio has soared by 110% YoY and by 68% from the previous quarter
Climb Bio's equity has soared by 109% from the previous quarter and by 98% YoY
CLYM's net income is down by 43% year-on-year
Climb Bio's EPS has decreased by 27% YoY
Key stats
What are the main financial stats of CLYM
Market
Valuations
Earnings
Shares outstanding
67.06M
Market cap
$311.16M
Enterprise value
$88.12M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.61
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$64.2M
EBITDA
-$63.84M
Free cash flow
$57,000
Per share
Balance sheet
Liquidity
EPS
-$2.15
Free cash flow per share
$0
Book value per share
$7.64
Revenue per share
$0
TBVPS
$7.45
Total assets
$226.02M
Total liabilities
$3.74M
Debt
$100,000
Equity
$222.28M
Working capital
$222.26M
Debt to equity
0
Current ratio
60.41
Quick ratio
59.65
Net debt/EBITDA
3.49
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-46%
Return on equity
-47%
Return on invested capital
-374.1%
Return on capital employed
-28.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CLYM stock price
How has the Climb Bio stock price performed over time
Intraday
-0.22%
1 week
-7.57%
1 month
-15.64%
1 year
75.76%
YTD
71.85%
QTD
-8.84%
Financial performance
How have Climb Bio's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$69.5M
Net income
-$64.2M
Gross margin
N/A
Net margin
N/A
CLYM's net income is down by 43% year-on-year
The operating income has contracted by 43% YoY
Growth
What is Climb Bio's growth rate over time
Valuation
What is Climb Bio stock price valuation
P/E
N/A
P/B
0.61
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Climb Bio's EPS has decreased by 27% YoY
Climb Bio's equity has soared by 109% from the previous quarter and by 98% YoY
The price to book (P/B) is 13% less than the last 4 quarters average of 0.7
Efficiency
How efficient is Climb Bio business performance
The return on assets has declined by 31% year-on-year
The company's return on equity fell by 29% YoY
Dividends
What is CLYM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CLYM.
Financial health
How did Climb Bio financials performed over time
CLYM's quick ratio has soared by 110% YoY and by 68% from the previous quarter
The total assets has surged by 107% since the previous quarter and by 94% year-on-year
CLYM's debt is 100% smaller than its equity
Climb Bio's equity has soared by 109% from the previous quarter and by 98% YoY
CLYM's debt to equity has shrunk by 100% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.